Loading...
•
Dec 31, 2022
Bicycle Q4 2022 Earnings Report
Bicycle Therapeutics reported financial results for the fourth quarter and full year ended December 31, 2022.
Key Takeaways
Bicycle Therapeutics reported its Q4 2022 financial results, highlighting clinical progress across its pipeline, including BT8009, BT5528, and BT7480. The company's cash position at the end of the year was $339.2 million, expected to provide financial runway into 2025.
Continued clinical progress was made across the pipeline, including advancing BT8009 and BT5528 into ongoing dose expansion cohorts.
BT8009 was granted Fast Track Designation by the U.S. Food and Drug Administration.
Phase I results for BT8009 were presented at the ASCO GU Cancers Symposium.
The company's cash position of $339.2 million at December 31, 2022, is expected to provide financial runway into 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...